Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …

Despite marked improvements in the survival of patients with severe lupus nephritis over the
past 50 years, the rate of complete clinical remission after immune suppression therapy is< …

Systemic lupus erythematosus (SLE) is an autoimmune disease mediated by pathogenic
autoantibodies directed against nucleoprotein complexes. Beyond the activation of …

Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus that can
lead to irreversible renal impairment. Although the prognosis of LN has improved …

Disease heterogeneity remains a major challenge for the understanding of systemic lupus
erythematosus (SLE). Recent work has revealed the important role of nonimmune factors in …

The immune pathways that define treatment response and non-response in lupus nephritis
(LN) are unknown. To characterize these intra-kidney pathways, transcriptomic analysis was …

To compare lupus pathogenesis in disparate tissues, we analyzed gene expression profiles
of human discoid lupus erythematosus (DLE) and lupus nephritis (LN). We found common …

Nephritis is a common complication of systemic lupus erythematosus for which current
therapies often prove inadequate. Current lupus nephritis classification systems emphasize …

The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for
the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares …

Lupus nephritis (LN), a major complication in individuals diagnosed with systemic lupus
erythematosus, substantially increases morbidity and mortality. Despite marked …